Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the dosing of the first patient in the Phase 2 DAVIO 2 clinical trial for EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD). The trial utilizes a 'Treat to Maintain' strategy, potentially reducing treatment frequency, as shown by Phase 1 results where 53% of patients didn't require additional treatment for six months. The Phase 2 trial will enroll around 150 patients, investigating the efficacy of EYP-1901 compared to aflibercept. Topline data is anticipated in the second half of 2023.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on August 3, 2022, at 8:30 a.m. ET to discuss its Q2 2022 financial results and recent corporate developments. The company focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its pipeline includes EYP-1901, targeting wet age-related macular degeneration. EyePoint's current marketed product is YUTIQ®, approved for chronic non-infectious uveitis. Interested parties can access the call via registration or by visiting the company website for a live audio webcast.
EyePoint Pharmaceuticals (NASDAQ: EYPT) recently shared promising 12-month safety and efficacy results from the Phase 1 DAVIO clinical trial for EYP-1901, aimed at treating wet AMD. The company expects to initiate dosing in a Phase 2 trial in Q3 2022 for both wet AMD and non-proliferative diabetic retinopathy. Q2 2022 net product revenue reached $11.3 million, a 30% increase year-over-year, with cash and investments totaling $171 million as of June 30, 2022. However, changes in reimbursement status for DEXYCU effective January 1, 2023, may pose financial challenges.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced the granting of stock options to nine new employees as inducement awards, in compliance with NASDAQ Listing Rule 5635(c)(4). A total of 18,000 options were issued on July 15, 2022, at an exercise price of $9.91, corresponding to the closing stock price on that date. The options will vest over four years, with 25% vesting on the first anniversary and the rest monthly thereafter. This strategic move aims to attract talented personnel to support the company's commitment to developing therapeutics for serious eye disorders.
EyePoint Pharmaceuticals announced positive 12-month results from the Phase 1 DAVIO clinical trial for EYP-1901, an anti-VEGF therapy aimed at treating wet AMD. The data revealed no ocular serious adverse events and stable visual acuity with a 35% rate of patients remaining supplement-free at 12 months. The company plans to initiate the Phase 2 trial (DAVIO2) in Q3 2022, targeting approximately 150 previously treated wet AMD patients. EYP-1901 shows promise for long-term maintenance therapy, with significant treatment burden reduction of 74% at 12 months.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host an Investor Day on July 18, 2022, from 8:00 a.m. to 11:00 a.m. ET. The event will feature commentary from the management team and guest speakers Carl Regillo, M.D., and Charles Wykoff, M.D., discussing the Durasert® drug delivery platform and the Phase 2 plans for EYP-1901, aimed at treating wet AMD. A live webcast will be available, with an archived replay accessible for 90 days post-event on the company's website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Karen Zaderej to its Board of Directors, bringing over 35 years of experience in biopharmaceuticals and medical devices. Zaderej is currently the President and CEO of AxoGen. Her expertise is expected to enhance EyePoint's strategic goals, particularly in advancing EYP-1901 for treating wet age-related macular degeneration (AMD). The investigational product utilizes EyePoint's proprietary Durasert technology, showing promising clinical data with 53% and 41% of treated eyes not requiring anti-VEGF injections up to six and nine months post-treatment.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the election of Dr. Anthony Adamis to its Board of Directors. Dr. Adamis, an accomplished ophthalmology executive with over 30 years in the biopharmaceutical industry, brings substantial experience in developing anti-VEGF drugs for eye diseases. His prior roles include Senior VP at Genentech/Roche and co-founder of EyeTech Pharmaceuticals. EyePoint aims to enhance its clinical trials for EYP-1901, a sustained delivery treatment for wet age-related macular degeneration. Phase 2 trials are expected in Q3 2022 and 2H 2022.
EyePoint Pharmaceuticals (NASDAQ: EYPT) and OcuMension Therapeutics have announced the approval of YUTIQ® in China for treating chronic non-infectious uveitis affecting the posterior segment of the eye. This approval makes YUTIQ the first drug authorized for commercialization in China based on real-world data. YUTIQ, which offers up to three years of continuous treatment, was previously approved by the FDA in 2018. The collaboration aims to enhance patient care in China, where approximately 1.4 million patients are affected by this condition.
On June 15, 2022, EyePoint Pharmaceuticals (NASDAQ: EYPT) granted stock options to nine new employees as part of their inducement awards outside the 2016 Long-Term Incentive Plan, aligning with NASDAQ Listing Rule 5635(c)(4). The total granted options amounted to 55,500 shares, with an exercise price of $7.93 per share, equal to the stock's closing price on the grant date. The options have a ten-year validity and vest over four years, contingent upon continued service with the company.
FAQ
What is the current stock price of EyePoint (EYPT)?
What is the market cap of EyePoint (EYPT)?
